Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody
about
The neurotransmitter dopamine modulates vascular permeability in the endotheliumContinuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicityTargeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcomaVEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedsideRemodeling Components of the Tumor Microenvironment to Enhance Cancer TherapyExploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunitiesThe role of vascular endothelial growth factor a polymorphisms in breast cancerTargeted nanotechnology for cancer imaging.Locoregional drug delivery using image-guided intra-arterial drug eluting bead therapyFibroblast Growth Factor 9 Imparts Hierarchy and Vasoreactivity to the Microcirculation of Renal Tumors and Suppresses MetastasesQuantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imagingThe alpha(1)beta(1) and alpha(2)beta(1) integrins provide critical support for vascular endothelial growth factor signaling, endothelial cell migration, and tumor angiogenesisInvestigation of the spatiotemporal responses of nanoparticles in tumor tissues with a small-scale mathematical model(3)D [corrected] quantification of tumor vasculature in lymphoma xenografts in NOD/SCID mice allows to detect differences among vascular-targeted therapiesA peptide corresponding to the neuropilin-1-binding site on VEGF165 induces apoptosis of neuropilin-1-expressing breast tumour cellsTargeting the vascular endothelial growth factor pathway in the treatment of human malignancy.Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma modelUltrasound ablation enhances drug accumulation and survival in mammary carcinoma modelsAnti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors.Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.Multifunctional polymeric micelles for delivery of drugs and siRNA.Vascular endothelial growth factor as an anti-angiogenic target for cancer therapyVascular normalization as a therapeutic strategy for malignant and nonmalignant disease.Normalization of the vasculature for treatment of cancer and other diseases.Preclinical molecular imaging of tumor angiogenesis.AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.An in vivo neovascularization assay for screening regulators of angiogenesis and assessing their effects on pre-existing vessels.Directed endothelial cell morphogenesis in micropatterned gelatin methacrylate hydrogels.Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy responseMetabolic tumor profiling with pH, oxygen, and glucose chemosensors on a quantum dot scaffold.Noninvasive evaluation of the vascular response to transplantation of alginate encapsulated islets using the dorsal skin-fold modelHCPTPA, a protein tyrosine phosphatase that regulates vascular endothelial growth factor receptor-mediated signal transduction and biological activity.A Validated Multiscale In-Silico Model for Mechano-sensitive Tumour Angiogenesis and Growth.A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor.A review of micro- and macrovascular analyses in the assessment of tumor-associated vasculature as visualized by MR.Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling.Mouse model of angiogenesisEffect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11.Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen.
P2860
Q24317718-C14FA296-6B3C-4592-B054-2CB231076D0EQ24561642-2B8685B9-56FF-43EC-ACCA-1B4051237D0BQ26747666-E6FB3A52-048A-49E2-A335-2C019F132C5CQ26770678-B7A2420E-5F42-4EA3-93AE-0BCFF0494805Q26777144-080F18FF-BD86-4191-9723-B834B58ABA99Q26828930-1323DA43-D14F-4B3E-84ED-F85C88297966Q26851522-CD1043E0-77E1-4756-B079-094FDD051ED2Q27010317-6836FFDA-61D7-4437-A097-F64D82F9153CQ27015918-4D5368AC-FEC3-4533-96D7-73E7D58953C3Q27312628-5CAE4A15-5C80-431F-9074-C1CCBBA94F9CQ27346895-A9EDF815-709B-4A5E-B0EC-9259ADAB1F49Q28344804-56E90190-BFD7-491C-BDC6-26E1414869D2Q28485922-62A8AD52-1813-4F6D-8B8C-49E8ACBFD948Q28488869-2A83BE0C-3D45-44DD-85E8-4DA4B09CFEE7Q29543360-26E6EB9E-711B-4ECC-AA3B-2E32A8AFECFEQ30358961-47506B73-8E92-4FB2-967F-36C7BB79823BQ30383248-B0548244-AD47-4598-BCE2-33A6CF45D39AQ30386783-76BC531D-13E9-4782-BDDF-5A7DEB768AC4Q30388655-7A1F4F68-54DB-4193-9BC5-B92D9241F2DEQ30399006-20F2A01E-A45C-405B-97A1-94A9C615026BQ30438973-DBE08653-C2B5-4F8F-9653-6FD9FFFFB15BQ30455612-25992D8B-D612-4590-858D-6B427F1C8C48Q30469815-646241DE-735E-49C5-8C14-232DD66EE405Q30471456-35EDA7FC-E456-4F2B-B0C0-66E9965BFF0BQ30475818-2A820B34-60C8-4DB4-B74C-7B97F5115530Q30490422-276BACB9-F1B0-4FC7-9DEE-BF1460B833E4Q30528295-20B32F83-FE97-4CAA-95FD-0E8B29D2FF29Q30539500-8348C3EE-37EF-4E64-94FF-38FC7BD80B05Q30542073-BAE891A1-E489-4E42-8996-1ED7A5758556Q30573416-85396E84-AB04-4635-86A3-C924272E8792Q30573562-5D50FD06-8457-4B19-8F0C-89B721C97B23Q30580697-D794E017-304F-45E0-8EE3-854870B04BE5Q30828692-98F8F157-1B5B-4BDE-9A91-94ADEA369358Q30836580-470AEA33-B52E-466E-BA9B-ED6796417D2EQ31104595-C9CFD984-2C53-4A40-ACCB-3AD284E883D4Q31113091-D1E3336D-2BBA-4C7C-B81B-DEA529269391Q31121875-43235BD5-ED63-469C-9D58-74291E0441D1Q32061166-E2B975AA-AC13-43FE-889F-4C729D10FC04Q33187344-DC30A56C-225F-4A55-AA1A-199B0ED734F7Q33392585-2A167879-8618-48E4-9AD2-95D5677A25FF
P2860
Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Time-dependent vascular regres ...... r permeability factor antibody
@en
Time-dependent vascular regres ...... permeability factor antibody.
@nl
type
label
Time-dependent vascular regres ...... r permeability factor antibody
@en
Time-dependent vascular regres ...... permeability factor antibody.
@nl
prefLabel
Time-dependent vascular regres ...... r permeability factor antibody
@en
Time-dependent vascular regres ...... permeability factor antibody.
@nl
P2093
P2860
P921
P356
P1476
Time-dependent vascular regres ...... r permeability factor antibody
@en
P2093
P2860
P304
14765-14770
P356
10.1073/PNAS.93.25.14765
P407
P577
1996-12-01T00:00:00Z